35.10
2.12%
0.73
Schlusskurs vom Vortag:
$34.37
Offen:
$35.05
24-Stunden-Volumen:
994.07K
Relative Volume:
0.48
Marktkapitalisierung:
$4.32B
Einnahmen:
$643.81M
Nettoeinkommen (Verlust:
$-490.76M
KGV:
-8.6453
EPS:
-4.06
Netto-Cashflow:
$-299.27M
1W Leistung:
+14.41%
1M Leistung:
+71.14%
6M Leistung:
+37.54%
1J Leistung:
+43.85%
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Vergleichen Sie GH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
35.10 | 4.32B | 643.81M | -490.76M | -299.27M | -4.06 |
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
2024-06-03 | Fortgesetzt | Jefferies | Buy |
2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
2023-12-14 | Eingeleitet | Guggenheim | Neutral |
2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-09-28 | Eingeleitet | Bernstein | Outperform |
2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
2023-05-05 | Eingeleitet | UBS | Buy |
2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-10-19 | Eingeleitet | Craig Hallum | Buy |
2022-10-06 | Eingeleitet | Stephens | Overweight |
2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
2022-04-28 | Fortgesetzt | BTIG Research | Buy |
2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
2022-02-24 | Bestätigt | Citigroup | Buy |
2022-02-24 | Bestätigt | Cowen | Outperform |
2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
2022-02-24 | Bestätigt | SVB Leerink | Outperform |
2022-02-24 | Bestätigt | Stifel | Buy |
2022-02-24 | Bestätigt | Wells Fargo | Overweight |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
2021-06-03 | Eingeleitet | Goldman | Buy |
2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
2021-01-11 | Eingeleitet | Stifel | Buy |
2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2020-06-12 | Eingeleitet | BTIG Research | Buy |
2020-02-21 | Eingeleitet | Guggenheim | Buy |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
2018-10-29 | Eingeleitet | JP Morgan | Overweight |
2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
KAS Team Wins $292.5 Million In Jury Trial of Guardant Health v. Natera - Morningstar
Advantage Alpha Capital Partners LP Buys New Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo Finance
Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera - MarketWatch
Guardant says jury unanimously found in favor of company in Natera suit - TipRanks
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims - MSN
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health Wins Historic $292.5M False Advertising Verdict Against Natera | NTRA Stock News - StockTitan
Natera Plans Appeal After Guardant Health Lawsuit Verdict, Defends Signatera Test Leadership | NTRA Stock News - StockTitan
BREAKING: Jury Finds Natera Owes Guardant $292.5M In False Ad Suit - Law360
Landscape Capital Management L.L.C. Acquires Shares of 31,448 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
(GH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Natera's Conduct 'Despicable,' Guardant Says As Trial Wraps - Law360
Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market - Insider Monkey
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
GH (Guardant Health) Operating Cash Flow per Share : $-2.10 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health Stock Sees RS Rating Jump To 83 - Yahoo! Voices
Guardant Health: Focused On Future Growth, Hold - Seeking Alpha
GH (Guardant Health) Free Cash Flow per Share : $-2.26 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health, Inc. (NASDAQ:GH) Q3 2024 Earnings Call Transcript - MSN
Guardant Health CIO Kumud Kalia sells $204,722 in stock - Investing.com India
Guardant Health Inc (GH) Shares Up 5.46% on Nov 19 - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Grows Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (FRA:5GH) Total Inventories : €65.1 Mil (As of Sep. 2024) - GuruFocus.com
Natera Exec Calls Guardant's Cancer Test Claims 'Dangerous' - Law360
Insider Selling: Director Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus.com
Guardant Health director Meghan Joyce sells $86,595 in stock - Investing.com
CADIAN CAPITAL MANAGEMENT, LP's Strategic Acquisition in Guardan - GuruFocus.com
Guardant Atty Accuses Natera CEO Of Dishonesty At Trial - Law360
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Baillie Gifford & Co. - MarketBeat
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR
Guardant Health Inc (GH) Stock Price Up 6.63% on Nov 13 - GuruFocus.com
Guardant CEO Says Rival's False Ads Hurt 'Beautiful Baby' - Law360
Multi-cancer Early Detection Market Next Big Thing| Major Giants Exact Sciences, AnchorDx, Guardant Health - openPR
Wellington Management Group LLP Bolsters Stake in Guardant Healt - GuruFocus.com
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher - Simply Wall St
Guardant Health, Inc. (NASDAQ:GH) Shares Bought by ARK Investment Management LLC - MarketBeat
Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Why Guardant Health Stock Blasted 13% Higher on Thursday - MSN
Ex-Natera VP Defends Ad Campaign Against Rival Guardant - Law360
Guardant Health (GH) Stock Surges on Strong Q3 Earnings - GuruFocus.com
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop - Yahoo! Voices
Leerink stays bullish on Guardant Health stock, citing robust growth prospects - Investing.com Canada
JPMorgan Chase & Co. Raises Guardant Health (NASDAQ:GH) Price Target to $50.00 - MarketBeat
Guardant Health (NASDAQ:GH) Shares Gap Up Following Analyst Upgrade - MarketBeat
Guardant Health (NASDAQ:GH) Price Target Raised to $36.00 at The Goldman Sachs Group - MarketBeat
Guardant Health Inc (GH) Trading 13.31% Higher on Nov 7 - GuruFocus.com
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Recor - GuruFocus.com
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):